When is bosulif patent expired?

See the DrugPatentWatch profile for bosulif

Patent Expiration Timeline for Bosulif

Bosulif (bosutinib) is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The patent for Bosulif is owned by Pfizer.

Patent Expiration Date

According to DrugPatentWatch.com, the patent for Bosulif expired on February 26, 2026.

Why is the Patent Expiration Relevant?

The expiration of the Bosulif patent has significant implications for patients, prescribers, and manufacturers. With the patent expiration, other companies may now develop and market biosimilars or generic versions of Bosulif, which could lead to increased competition and potentially lower prices.

Potential Impact on Prices

The entry of generic or biosimilar versions of Bosulif into the market may lead to increased competition and lower prices. This could be beneficial for patients who rely on this medication for their treatment.

Future Developments

As the patent expiration approaches, patients and healthcare providers should be aware of any potential changes to the availability and pricing of Bosulif.

Sources:

1. DrugPatentWatch.com DrugPatentWatch.com
2. Pfizer.com - [Pfizer.com](https://www.pfizer.com/news/important-safety-information-and-boxed-warnings/ bosutinib)

Note: The information provided is accurate as of June 25, 2026, and subject to change.